Serological responses to 60-day and 30-day nifurtimox treatment using ELISA F29 over the study period (FAS).
A total of 99 of the 295 patients (33.6%) showed negative ELISA F29 values at baseline, and the proportion of such patients was similar in the two nifurtimox treatment groups (60-day regimen: 67 patients [34.0%]; 30-day regimen: 32 patients [32.7%]) (